Why API price needs to be part of NPPA’s pricing formula
The over-dependence on China and other countries imperils not just the health of the pharma industry in India, but also that of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Will regulators catch up in 2020?
The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?
Rationalising pharma trade margins seems next on the list
Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…
Lupin sells stakes in Kyowa but its not a Sayonara
With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…
After sartans and ranitidine, where will NDMA show up next?
While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…
Slaying GMP non-compliance woes
Multiple warning letters call for renewed rigour to fix recurring lapses and instil a stronger quality compliance system
Heeding the clarion call for sustainability
New and existing pharma facilities will have to meet higher benchmarks to ensure that they do not pollute the environment…
Price caps are a band aid hiding larger issues
Pharma companies should not be the ones held responsible for the high prices of medicines
CDSCO is blowin’ in the wind
The CBI has reportedly found cases with the same modus operandi: failing batches and then approving them for a price
Big Pharma to get bigger, but what about patients?
The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…
Protect IP to grow GDP
The RCEP negotiation is one of the BJP-led NDA-2 government’s first challenges as it links directly to the stated goal to make…
Time for a policy push for pharma
Delayed implementation of the API policy has resulted in India’s dependence on China
Will NDA-2’s first budget be any different for the pharma sector?
With actual fiscal outcomes for FY19 falling short of the revenue estimates put out in the interim budget, FM Sitharaman will have…
A silver lining to withdrawal of GSP benefits?
Will US President Trump’s mission to Make America Great Again turn out to be a great fillip for PM Modi’s Make in India campaign?…
Own up, course correct and move on
Rather than living in denial and shooting the messenger (Eban in this case), pharma companies have to own up to their mistakes,…
Post USTR Special 301 Report, pragmatism wins over confrontation?
While both governments continue the dialogue, there are various groups working to find a middle path
India on USTR’s Priority ~ Watch List again
Will we be safeguarding our national health priorities and standards if we toe the USTR’s line or get a better rank on the GIPC IP…
Cracking the cGMP code
Even if top management walks the talk, are these concepts filtering down to all employees, especially those at manufacturing…
Patient care apps serve a purpose, but need to be closely monitored
Besides concerns on data privacy, aren’t such digital initiatives vulnerable to conflict of interests, and merely another…
Stree Shakti in the CDSCO!
With women heading Nigeria's NAFDAC, FDA Ghana and FDA Ivory Coast, India could also have a woman DCGI in the not so very distant…